US Archives - Page 62 of 100 - European Medical Journal

EMJ

Prof Ian C. Chikanza

Consultant, Adult and Paediatric Rheumatology, Department of Rheumatology, Barts Arthritis Centre, Barts and The Royal London Hospital…

EMJ

Dr Aysen Akinci

Professor, Physical Medicine and Rehabilitation; Rheumatologist and Pain Medicine Specialist, Department of Physical Medicine and…

EMJ

Dr Elena Myasoedova

Professor of Medicine; Consultant, Rheumatology and Epidemiology; Director, Inflammatory Arthritis Clinic, Mayo Clinic Rochester…

Need for Diverse Populations in Epilepsy Research: AES 2024

The lack of diversity not only limits equitable care but also hinders scientific understanding of epilepsy.

No Benefit from Chest Wall Irradiation in Intermediate-Risk Breast Cancer: SABCS 2024

Avoiding chest wall irradiation post-mastectomy is safe for most intermediate-risk breast cancer patients, improving quality of care.

Deep Learning Tool Predicts Immunotherapy Efficacy in Lung Cancer

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).

What Do Migraine And Gastrointestinal Disorders Have In Common?

A study has uncovered significant genetic overlap between migraine and several gastrointestinal (GI) disorders, suggesting shared underlying neurologic mechanisms despite diverse etiologies.

Ultrasound Technique Offers Hope for Preventing Epilepsy: AES 2024

Low-intensity focused ultrasound (LOFU) shows promise as a non-invasive treatment for temporal lobe epilepsy (TLE).

COMET Trial Explores DCIS Treatment Dilemma: SABCS 2024

Patients with low-risk ductal carcinoma in situ (DCIS) who chose active monitoring over immediate surgery reported similar quality-of-life outcomes, according to findings from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Data, Risks, and Mortality Rates Of Fungal Infections After HSCT

A recent multicenter study in China provides critical insights into the persistent threat of invasive fungal disease (IFD) among patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).